First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
- Conditions
- Peripheral Artery DiseaseFemoropopliteal Artery Disease
- Interventions
- Device: Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)Drug: Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)
- Registration Number
- NCT02145065
- Lead Sponsor
- Balton Sp.zo.o.
- Brief Summary
The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.
- Detailed Description
Although clinically effective, the manufacturing process of first generation PCB coatings contributed to inconsistent drug concentrations, particulate formations on the balloon surface and their shedding during the interventional procedures. As a consequence developments of new PCB coatings have been proposed to address consistency, uniformity, small particle drug coverage, which may potentially contribute to improved vessel healing profile and improved clinical outcomes. Nevertheless, data on the safety and efficacy of this novel coating developments in the clinical setting remain limited. Previously in the experimental model, the investigators reported that delivery of paclitaxel via a novel mcPCB resulted in low long-term tissue retention of paclitaxel, however displayed reduced neointimal proliferation and favorable healing profile. Therefore in current clinical trial the investigators will address the feasibility and safety of the mcPCB (PAK, Balton) in the treatment of femoropopliteal restenotic disease in a prospective, randomized manner when compared to plain balloon angioplasty (PBA). The efficacy analysis will be observational and evaluated post-hoc, with no prespecified criteria.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 66
- Age > 18 y.o.
- Claudication in Rutherford Class 1-5,
- Lesion in the femoropopliteal artery defined as >50% and < 99% diameter stenosis with length of up to 10 cm in vessel diameter of 3-7 mm
- Chronic total occlusions of length less than 100 mm
- Ability to cross the lesions with a guidewire.
- Critical acute or chronic limb ischemia
- Acute coronary syndrome
- Chronic kidney disease stage III-V
- Restenotic lesion
- Femoropopliteal graft
- Known allergy to clopidogrel or aspirin
- History of stroke within past 6 months
- Age > 80 y.o.
- Life expectancy < 2 years
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Plain Balloon Angioplasty Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland) Plain Balloon Angioplasty microcrystalline Paclitaxel Coated Balloon (PAK) Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland) plain balloon angioplasty followed by mcPCB dilation
- Primary Outcome Measures
Name Time Method Angiographic late lumen loss 6 months
- Secondary Outcome Measures
Name Time Method Safety - Device related adverse events 30 days, 6 months Device Success at procedure Successful delivery and deployment of the first inserted study device (in overlapping setting a successful delivery and deployment of the first and second study device) at the intended target lesion and successful withdrawal of the study device with attainment of final residual stenosis of less than 30% of the target lesion by quantitative vessel angiography (QVA).
Critical limb ischemia 30 days, 6 months Target Lesion Revascularization 6, 12, 24 months Target vessel revascularization 6, 12, 24 months Primary patency of treated segment 6, 12, 24 months Treated limb amputation 30 days, 6 months
Trial Locations
- Locations (1)
Lesser-Poland Cardiovascular Center of American Heart of Poland
🇵🇱Chrzanów, Poland